back to top
HomeTagsFSGS

FSGS

Travere Therapeutics Presents Knowledge Reinforcing Medical Advantage of FILSPARI ® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024 By...

Practically 60% of sufferers with IgAN within the SPARTAN Examine achieved full remission when utilizing FILSPARI as first-line therapy SPARTACUS Examine, PROTECT open-label extension,...

Most Popular

spot_img